TG Therapeutics Q2 2024 GAAP EPS $0.04 Beats $(0.05) Estimate, Sales $73.466M Beat $65.893M Estimate
Portfolio Pulse from Benzinga Newsdesk
TG Therapeutics (NASDAQ:TGTX) reported Q2 2024 GAAP EPS of $0.04, beating the $(0.05) estimate by 180%. Sales were $73.466M, surpassing the $65.893M estimate by 11.49% and marking a 357.05% increase from the same period last year.
August 06, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TG Therapeutics reported Q2 2024 GAAP EPS of $0.04, significantly beating the $(0.05) estimate. Sales were $73.466M, surpassing the $65.893M estimate and showing a 357.05% increase from the same period last year.
The significant beat on both EPS and sales estimates, along with a substantial year-over-year sales increase, is likely to positively impact TGTX's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100